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Pathogenic Variants for Mendelian and Complex Traits
in Exomes of 6,517 European and African Americans:
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Holly K. Tabor,1,2,9 Paul L. Auer,3,4,9 Seema M. Jamal,2 Jessica X. Chong,2 Joon-Ho Yu,2
Adam S. Gordon,5 Timothy A. Graubert,6 Christopher J. O’Donnell,7 Stephen S. Rich,8
Deborah A. Nickerson,5 NHLBI Exome Sequencing Project, and Michael J. Bamshad2,5,*
Exome sequencing (ES) is rapidly being deployed for use in clinical settings despite limited empirical data about the number and types of
incidental results (with potential clinical utility) that could be offered for return to an individual. We analyzed deidentified ES data from
6,517 participants (2,204 African Americans and 4,313 European Americans) from the National Heart, Lung, and Blood Institute Exome
Sequencing Project. We characterized the frequencies of pathogenic alleles in genes underlying Mendelian conditions commonly
assessed by newborn-screening (NBS, n ¼ 39) programs, genes associated with age-related macular degeneration (ARMD, n ¼ 17),
and genes known to influence drug response (PGx, n ¼ 14). From these 70 genes, we identified 10,789 variants and curated them by
manual review of OMIM, HGMD, locus-specific databases, or primary literature to a total of 399 validated pathogenic variants. The
mean number of risk alleles per individual was 15.3. Every individual had at least five known PGx alleles, 99% of individuals had at least
one ARMD risk allele, and 45% of individuals were carriers for at least one pathogenic NBS allele. The carrier burden for severe recessive
childhood disorders was 0.57. Our results demonstrate that risk alleles of potential clinical utility for bothMendelian and complex traits
are detectable in every individual. These findings highlight the necessity of developing guidelines and policies that consider the return of
results to all individuals and underscore the need to develop innovative approaches and tools that enable individuals to exercise their
choice about the return of incidental results.Introduction
Exome sequencing and whole-genome sequencing (ES/
WGS) are highly effective tools for identifying the genetic
basis of heritable disorders, and their use in clinical settings
is rapidly increasing.1–3 Aside from identifying the vari-
ant(s) underlying the disorder for which sequencing was
performed (i.e., the primary result), ES/WGS can identify
other variants (i.e., secondary or incidental results) that
could be of clinical and/or personal (e.g., reproductive
planning or lifestyle modification) utility.4 The ability to
identify incidental results has led to considerable contro-
versy about whether such variants should be reported to
individuals and/or families in clinical settings and research
participants and, if so, how they should be offered for re-
turn.5–10 Clinical utility is defined as the existence of estab-
lished therapeutic interventions or actions that have the
potential to change the clinical course of disease,11
whereas personal utility is more broadly debated and can
include reproductive decision making, lifestyle changes
with a less direct impact on disease risk, and life plan-
ning.12 Several recent studies have demonstrated that per-
sonal utility is an important consideration for individuals
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The Amersions about the return of genetic results, given that the
vast majority of individuals indicate that they want access
to a broad range of results beyond those with a direct
clinical benefit.13–15 Recently published results of survey
responses from ~900 genetic professionals suggest that
genetics care providers also value the potential benefit of
results of personal utility and think they should be offered
for return.16
Frequently, the debate about the return of incidental re-
sults from ES/WGS has been framed by major gaps in
knowledge: (1) the frequency with which incidental results
that prompt clinical action (i.e., changes in medical man-
agement) are identified in ES/WGS data5,6 and (2) the
extent to which the process of curating and reporting
such variants is beyond what is required to answer a clin-
ical question.5 Yet, how much weight these issues should
be given has been informed to only a very limited extent
by empirical data on the effectiveness of curating large
ES/WGS data sets for well-known pathogenic risk variants,
the proportion of individuals who have known risk vari-
ants for disease, and the number and kinds of risk variants
(i.e., burden) found in each individual.10,17–22
Most recent attempts to estimate the number of pre-
dicted or known pathogenic variants in subsets of genesute, Seattle, WA 98101, USA; 2Department of Pediatrics, University of Wash-
hinson Cancer Research Center, Seattle, WA 98109, USA; 4School of Public
artment of Genome Sciences, University of Washington, Seattle, WA 98195,
7Cardiovascular Epidemiology and Human Genomics Branch, Division of
MA 01702, USA; 8Department of Public Health Sciences, University of Vir-
y of Human Genetics. All rights reserved.
ican Journal of Human Genetics 95, 183–193, August 7, 2014 183
underlying various phenotypes in certain populations18,23
have focused on identifying large-effect variants with high
clinical impact for very rare autosomal-recessive and auto-
somal-dominant conditions.10,17–23 The prior probability
of finding risk variants that underlie most rare Mendelian
conditions is very low. This fosters screening of relatively
large numbers of genes with little expectation that variants
of known pathogenic significance will be found in many
individuals. For example, recommendations from the
American College of Medical Genetics and Genomics
(ACMG) on the return of incidental results from 56 genes
captured by exome sequencing suggest that only 1% of in-
dividuals will have a result to return.24 Moreover, the large-
effect alleles that underlie Mendelian conditions represent
a small fraction of the risk variants that could be of utility
for an individual. In other words, risk variants underlying
more common complex diseases also need to be consid-
ered for return. With this in mind, it has been emphasized
that every individual most likely has an ES/WGS result(s)
that could be offered for return.25 Yet, there is scant empir-
ical evidence from assessments of large ES/WGS data sets to
support this claim.
To characterize the broad range of risk alleles that could
be offered for return in individuals who undergo ES/WGS
and to better frame the debate about the return of inci-
dental results, we sought to address four major questions
about the spectrum of genetic results of potential utility,
both clinical and personal, in both individual exomes
and collectively in a large set of exomes sampled from
European American (EA) and African American (AA) indi-
viduals: for genes associated with common Mendelian
conditions and common complex diseases, (1) what is
the per-individual burden of pathogenic risk variants, (2)
what is the cumulative burden of risk variants per individ-
ual, (3) how well do computational predictors of delete-
rious variants identify known disease-risk variants, and
(4) what are the implications of estimates of per-individual
burden of variants of utility for the management of inci-
dental results from ES/WGS?
We assessed protein-coding variants in health-related
genes in 6,517 individuals enrolled in the National Heart,
Lung, and Blood Institute (NHLBI) Exome Sequencing Proj-
ect (ESP). TheESPdata set consistsofhigh-coverage (average
median depth ~ 903) exome sequences from 2,204 AA and
4,313 EA individuals sampled from more than 20 cohorts
with heart and lung phenotypes unrelated to those condi-
tions assessed herein (Table S1, available online).26
In this ESP data set, we identified pathogenic variants in
three broad categories that represent the spectrum of po-
tential utility and across a range of allele frequencies and
disease prevalences. The first category included 39 genes
underlying 31 Mendelian conditions, most of which are
inborn errors of metabolism, recommended for newborn
screening (NBS) (Table S2) by the Discretionary Advisory
Committee on Heritable Disorders in Newborns and Chil-
dren (formerly known as the Secretary’s Advisory Commit-
tee on Heritable Disorders in Newborns and Children) Rec-184 The American Journal of Human Genetics 95, 183–193, August 7ommended Uniform Screening Panel (Table S2). NBS
results in adults are primarily of personal utility because
they can be used for reproductive planning.
The second category included 17 genes associated
with risk of age-related macular degeneration (ARMD)
(Table S2). ARMD is a common complex condition with
onset late in life and a relatively high frequency and is
the third leading cause of vision loss worldwide.27 Many
healthy adults are likely to carry ARMD risk variants, and
at present there are limited interventions to prevent or
mitigate ARMD. Therefore, ARMD results are primarily of
utility for potential early risk identification, improved
diagnosis, and delay of onset and/or mitigation of symp-
toms through lifestyle modifications (e.g., diet, vitamin
supplementation, and smoking cessation), as well as life
planning. In the future, such results might allow for risk
stratification and targeted interventions.27,28
The third category included 14 genes containing variants
known to influence drug response (PGx) (Table S2). PGx re-
sults are primarily of utility for the avoidance of adverse re-
actions or lack of response to certain medications across a
range of clinical conditions or settings. Our selection
criteria for this set depended upon the higher levels
of evidence of association in the PharmGKB database,
including replicated studies with significant p values and/
or medical-society-endorsed PGx guidelines. Although the
relative risks for these variants vary, their clinical utility
and functional significance are well documented. Conse-
quences for these variants range from severe allergic reac-
tions to a lack of response to a range of drugs, including
blood-thinning agents, antipsychotic medications, and
chemotherapeutic agents.29–31
We annotated all variants in each of these 70 genes with
commonly available computational-prediction approaches
and manually curated them to determine whether they
were pathogenic. We subsequently compared the effective-
ness of computational predictions of known risk variants
and generated individual and population-specific estimates
of the burden of risk variants for Mendelian and complex
traits in the NBS, ARMD, and PGx gene sets.Material and Methods
Exome Sequencing and Variant Calling
Library construction, exome capture, sequencing, and mapping
were performed as previously described.26 Sequencing was per-
formed at the University ofWashington (UW) and the Broad Insti-
tute of MIT and Harvard (Broad). In brief, exome capture was
performed with the Roche Nimblegen SeqCap EZ Library or the
Agilent SureSelect Human All Exon 50 Mb Kit. Paired-end
sequencing (2 3 76 bp) was performed on Illumina GAII and
HiSeq instruments. Single-nucleotide variants (SNVs) were called
with a maximum-likelihood approach32 implemented in the
UMAKE pipeline at the University of Michigan, which allowed
all samples to be analyzed simultaneously for both variant calling
and filtering. BAM33 files summarizing Burrows-Wheeler Aligner34
alignments generated at the UWand the Broad were used as input., 2014
BAMfiles summarized alignments mapped to the GRCh37 human
reference sequence and were refined by duplicate removal, recali-
bration, and indel realignment with the Genome Analysis
Toolkit.35 We excluded all reads that were not confidently mapped
(Phred-scaled mapping quality < 20) from further analysis. We
then used SAMtools33 to compute genotype likelihoods for exome
targeted regions and 50 flanking bases while accounting for per-
base alignment quality. We identified variable sites and their allele
frequencies by using a maximum-likelihood model implemented
in glfMultiples.32 These analyses assumed a uniform prior proba-
bility of polymorphism at each site. The final call set was per-
formed on 6,823 samples.
We used a support vector machine (SVM) classifier to separate
most likely true-positive and false-positive variant sites with the
use of various quality metrics. These included allelic balance (the
proportional representation of each allele in likely heterozygotes),
base-quality distribution for sites supporting the reference and
alternate alleles, and the distribution of supporting evidence be-
tween strands and sequencing cycle, among others. We used vari-
ants identified by dbSNP or 1000 Genomes36 as the positive
training set and used variants that failed multiple filters as the
negative training set. This method was effective at removing
sequencing artifacts while preserving good-quality data, as indi-
cated by the transition-transversion ratio for previously known
and newly identified variant sites, the proportion of high-fre-
quency variants overlapping with dbSNP, and the ratio of synony-
mous to nonsynonymous variants, as well as attempts at validating
a subset of sites. A total of 1,908,614 SNVs passed the SVM filter.
In order to obtain high-quality genotypes for estimating allele
frequency and carrier burden, we set individual genotypes to
missing if the corresponding read depth was <103. We also
excluded variants with read depth > 5003. With the exception
of one outlier with a low call rate, all samples had high call rates.
The outlier was removed from the analysis.Identification of Related Individuals and Ancestry
Designation
We used principal-component analysis (PCA) to assign genetic
ancestry. Only autosomal SNVs with a minor allele frequency
(MAF) R 0.1% and a call rate > 95% were included in the PCA,
which we executed in PLINK37 after pruning SNVs in linkage
disequilibrium. The first two principal components clearly sepa-
rated AA samples from EA samples (Figure S1). Thirty individuals
of indeterminate genetic ancestry (i.e., located between the two
vertical lines in Figure S1) were removed.
After designating samples to AA and EA ancestry groups, we used
KING38 to run a kinship analysis stratified by genetic-ancestry
assignment to identify cryptically related individuals. Pairs of sam-
ples with a kinship-coefficient range of >0.354, [0.177, 0.354],
[0.0884, 0.177], and [0.0442, 0.0884]weredesignatedas duplicates,
first-degree relatives, second-degree relatives, and third-degree rela-
tives, respectively. Only the samplewith the higher overall call rate
from each duplicate or relative pair was retained. This resulted
in the removal of 274 samples from analysis. We also estimated
inbreeding coefficients for each pair of samples and removed
one sample with a value higher than that of all other samples.
This resulted in a final data set of 2,204 AA and 4,313 EA samples
(total ¼ 6,517), hereafter referred to as ESP6500.
The 6,517 ESP samples contained 422 samples from cystic-
fibrosis (CF [MIM 219700])-affected individuals who were known
carriers for pathogenicCFTRmutations.We excluded these 422 CFThe Amerindividuals from the CFTR carrier-burden and risk-variant fre-
quency estimates described in the Results.
Annotation and Selection of Risk Variants
Variants that were polymorphic and had a call rate R 90% in
ESP6500 were submitted to the SeattleSeq Annotation server on
May 29, 2012. We used SeattleSeq Annotation 134, the hg19 build
of the human reference genome (UCSCGenome Browser), and the
NCBI full genes (NM, XM) gene-model option. For variants map-
ping to multiple transcripts, we retained the most damaging
classification (from most to least damaging: nonsense, splice,
missense, synonymous, UTR, other). PolyPhen-239 scores were ob-
tained from the PolyPhen-2 server with the use of the HumDiv
classifier model. Combined Annotation-Dependent Depletion
(CADD) scores were obtained from the CADD server.40
All annotated variants from the 70 genes selected for assessment
were entered into a spreadsheet for curation. Each variant was
manually compared to variants in the Human Gene Mutation
Database (HGMD Professional 2012.3) and Online Mendelian In-
heritance in Man (OMIM) by either rsID or by protein position.
Variants not found in OMIM or HGMD in the PGx and ARMD
gene sets and variants not found inOMIMor HGMD as either ‘‘dis-
ease mutation’’ (DM) or ‘‘disease mutation?’’ (DM?) in the NBS
gene set were eliminated from further consideration (i.e., exclu-
sion step 1; Table S3 and Figure S2). Next, we eliminated variants
listed in HGMD or OMIM but associated with a phenotype that
differed from the one for which screening was intended, those
listed as polymorphic in one of 27 locus-specific databases
(LSDBs), and those not in PharmGKB (Tables S2 and S4; exclusion
step 2 in Figure S2). We then excluded variants with a call rate <
90% in either EA or AA individuals (exclusion step 3; Table S3
and Figure S2). Lastly, we excluded ten NBS variants that were ho-
mozygous in the absence of compelling evidence, via literature re-
view, of disease causality and three NBS variants that had an allele
frequency > 3% (suggesting that they were polymorphisms rather
than risk variants for a rare Mendelian disorder and/or had
recently been shown not to be pathogenic); excluded PGx variants
that had the lowest level of evidence of functional significance
(i.e., level 4) in PharmGKB; and excluded ARMD variants for
which clinical testing was not available per GeneTests (exclusion
step 4; Table S3 and Figure S2). We included all nonsense variants
that had not been observed previously, all of which were
singletons.
The institutional review boards at all participating sites
approved the NHLBI ESP study protocols.Results
Curation of Variants
We identified a total of 10,879 different variants (i.e.,
candidate-variant set) in 70 disease-related genes in the
6,517 ESP samples. A total of 5,155 variants in AA individ-
uals and 5,724 variants in EA individuals were found. As
anticipated, manual comparison of the set of candidate
variants to HGMD and OMIM resulted in a substantial
reduction in the number of variants retained for further re-
view; 91%, 92%, and 90% of variants were excluded in the
total sample, in AA individuals, and in EA individuals,
respectively (Table S3). A larger fraction of variants were
excluded in the ARMD (94%) and PGx (94%) gene setsican Journal of Human Genetics 95, 183–193, August 7, 2014 185
than in the NBS gene set (86%) partly because of the reten-
tion of a larger fraction of rare variants in the NBS gene set.
To evaluate the extent to which the curation process en-
riched the set of risk variants with those likely to confer
disease risk, we compared metrics of evolutionary conser-
vation, pathogenicity, and deleteriousness between the
set of risk variants and the variants that were excluded
from further analysis. A Genome Evolutionary Rate
Profiling (GERP) score is a measure of evolutionary
constraint, such that high GERP scores reflect the strength
of past purifying selection.41 Heuristically, variants with
high GERP scores are more likely to exert phenotypic con-
sequences than variants with lowGERP scores. Mean GERP
scores of variants in the risk set were significantly higher
than the mean scores of the excluded variants (Figure 1)
for NBS (p ¼ 1.45 3 1086) and ARMD (p ¼ 4.40 3 104)
gene sets, but not for the PGx gene set (p ¼ 0.066).
PolyPhen-2 scores are a measure of the impact of an
amino acid substitution on the structure and function of
a protein.39 Variants with PolyPhen-2 scores nearer to 1
are predicted to be damaging, whereas scores close to
0 are less likely to affect protein function. There were
significantly more damaging variants in the NBS set of
risk variants than among excluded variants (p ¼ 1.99 3
1019; Figure 1). The difference was not significant for
the ARMD (p ¼ 0.42) or PGx (p ¼ 0.25) variant sets.
CADD scores provide another means of prioritizing var-
iants. Larger CADD scores correspond to variants that are
more likely to be deleterious in terms of overall organismal
fitness.40 CADD scores are available for all 8.6 billion
possible SNVs in the human genome and are Phred scaled.
There were significantly more damaging variants in the
NBS set of risk variants than among excluded variants
(p¼ 1.383 10109; Figure 1). The difference was still signif-
icant but less striking for ARMD (p ¼ 9.9 3 104) and PGx
(p ¼ 1.47 3 109) variant sets, consistent with the predic-
tion that variants underlying rare, Mendelian disorders are
highly deleterious whereas variants for complex pheno-
types (e.g., ARMD) and phenotypes with low to modest
effects on fitness (e.g., PGx) are less deleterious.
Whereas the percentage of variants retained in the
ARMD and PGx variant sets was similar between AA and
EA individuals, the percentage of variants retained in the
NBS gene set was substantially higher in EA individuals
(15%) than in AA individuals (10%). This observation
raised the possibility that a greater fraction of true risk var-
iants in AA individuals were being excluded as a result of
underrepresentation of pathogenic rare variants in AA in-
dividuals in HGMD and/or OMIM.42 If this was the case,
one prediction is that compared to rare variants excluded
in EA individuals, rare variants excluded in AA individuals
should be enriched with predicted deleterious variants.
However, the mean GERP, PolyPhen-2, and CADD scores
did not differ significantly.
Because the allele frequencies of variants that cause
inborn errors of metabolism assessed via NBS are generally
well known, we compared the allele frequency of each NBS186 The American Journal of Human Genetics 95, 183–193, August 7risk variant with aMAF> 1% in ESP6500 to estimates from
1000 Genomes data. Allele frequencies were similar except
for rs334, the variant underlying sickle cell disease (MIM
603903), which had a MAF of only 4.0% in ESP6500 but
an MAF of 9.0% in the 1000 Genomes data (Table S5).
We also estimated carrier frequencies ofmany of the con-
ditions in the NBS gene set in order to compare our
estimates to those previously published. For several condi-
tions, our observed carrier frequencies were higher than
published estimates (Table S6). Our original strategy for
curating variants included HGMD, OMIM, and LSDB vari-
ants that could be identified during NBS but thatmight not
cause a phenotype (e.g., pseudodeficiency or partial-defi-
ciency alleles) requiring treatment. As a consequence, our
observed carrier-frequency estimates for some NBS condi-
tions were inflated. For this reason, we performed an addi-
tional step of manually reviewing variants listed in HGMD
as DM? (n¼ 12); variants present as homozygotes in either
EA or AA individuals and/or variants with aMAF> 0.5% in
either EA or AA individuals (n ¼ 15) (Table S7); all variants
in CFTR (MIM 602421) (n ¼ 60); and PAH (MIM 261600)
variants listed in HGMD as ‘‘hyperphenylalaninemia’’
(MIM 261600) (n ¼ 13). Hyperphenylalaninemia is de-
tected by NBS but is not associated with clinical or symp-
tomatic phenylketonuria (MIM261600). Detailedmethods
of this additional review are described in Table S6, and the
revised carrier frequencies are shown in Table S7.
For the majority of examined NBS conditions, our orig-
inal and revised carrier-frequency estimates were similar
to, and often lower than, population-based estimates of
carrier frequencies (Figure 2). For example, our review of
variants for congenital adrenal hyperplasia (MIM
201910) eliminated the only two potentially pathogenic
variants in ESP6500. This resulted in a carrier frequency
of 0, which is unrealistic given that the published carrier
frequency is 1/61. This result suggests that our additional
review to attempt to generate more accurate estimates of
carrier frequencies was too strict for many conditions.
This observation is consistent with the fact that patho-
genic copy-number variants (CNVs), indels, and variants
outside of the target were not included in the ESP6500
data set.
Distribution of Risk Variants
In the overall EA and AA samples, a total of 399 validated
risk variants (i.e., risk-variant set) were identified in 6,517
individuals in the NBS gene set (n ¼ 328), the ARMD
gene set (n ¼ 25), and the PGx gene set (n ¼ 46)
(Table S8). The majority (87%) of variants were rare
(MAF% 0.5%), and as expected given the predicted pheno-
typic consequences of risk variants in each gene set, there
was a higher percentage of rare variants in the NBS gene set
(96%) than in either the ARMD set (68%) or the PGx set
(39%). As a corollary, the site-frequency spectrum of risk
variants underlying PGx and ARMD phenotypes included
a higher percentage of variants of intermediate (1%<MAF
< 5%) and high (MAF R 5%) frequency (Figure S3)., 2014
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Figure 1. Extent to which the Variant-Curation Process Enriched the Risk-Variant Set with Those that Most Likely Confer Disease Risk
Violin plots showing the distribution of metrics of conservation (A), pathogenicity (B), and deleteriousness (C) between included and
excluded variants in the NBS, ARMD, and PGx gene sets.
(A) Mean GERP scores of variants in the risk set were significantly higher than the mean scores of the excluded variants for the NBS (p ¼
1.45 3 1086) and ARMD (p ¼ 4.40 3 104) gene sets, but not for the PGx gene set (p ¼ 0.066).
(B) Significantly more variants were predicted to be probably damaging (blue) by PolyPhen-2 in the NBS (p ¼ 1.99 3 1019) and ARMD
(p¼ 0.42) gene sets than in the PGx gene set (p¼ 0.25). The fraction of variants predicted to be benign (red) or possibly damaging (green)
is denoted.
(C) With the use of CADD scores, significantly more damaging variants were found in the NBS (p ¼ 1.38 3 10109), ARMD (p ¼
9.9 3 104), and PGx (p ¼ 1.47 3 109) risk-variant sets.A total of 309 and 197 risk variants were identified in EA
and AA individuals, respectively. The higher number of
risk variants in EA individuals was partly due to the fact
that a larger number of EA individuals (n ¼ 4,313) than
AA individuals (n ¼ 2,204) were sequenced. The overallThe Amerdistribution of risk variants of rare, intermediate, and
high frequency in both EA and AA individuals was similar
to that observed for the total sample. The percentage of
rare risk variants in each gene set was slightly higher in
EA than in AA individuals, and a higher fraction of rareican Journal of Human Genetics 95, 183–193, August 7, 2014 187
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Figure 2. Comparison of Published versus Observed Carrier
Estimates for NBS Conditions
Published estimates of carrier frequencies were similar to estimates
on the basis of a conservative manual review of NBS risk variants.
Carrier estimates for sickle cell anemia (MIM 603903), beta-thalas-
semia (MIM 613985), and hemoglobin C disease (MIM 141900.
0038) were calculated in AA individuals separately (red), and esti-
mates for CF (MIM 219700) were calculated in AA (red) and EA
(green) individuals separately, whereas all other estimates were
calculated in the total ESP6500 sample (blue).risk variants in each gene set in EA individuals had never
been observed. Most risk variants that were of rare or inter-
mediate frequency were specific to EA or AA individuals;
however, most of the risk variants of intermediate fre-
quency for ARMD were shared by both AA and EA
individuals.
Burden of Risk Alleles per Individual
The mean number of risk alleles per individual in the NBS
gene set was 0.57 (0.60 in EA individuals and 0.51 in AA in-
dividuals). This diminished to 0.18 overall (0.17 in EA
individuals and 0.22 in AA individuals) if we excluded all
variants that are typically reported and therefore of poten-
tial personal utility but for which it is quite unclear
whether they are truly pathogenic. In both EA and AA in-
dividuals, 45% had at least one and 11% had at least two
pathogenic alleles in the NBS gene set (Figure 3A). The
maximum number of pathogenic alleles per individual
was four in AA individuals (n ¼ 2) and five in EA individ-
uals (n ¼ 1). Two pathogenic variants of intermediate or
higher frequency accounted for the majority (68%) of
pathogenic alleles found in each individual. The most
common pathogenic variant (allele frequency ¼ 7.2%
[9.4% in EA individuals and 2.9% in AA individuals]) in
the NBS gene set was c.940A>G (p.Asn314Asp)
(rs2070074, or the Duarte allele) in GALT (MIM 606999),
mutations in which cause classical galactosemia (MIM
230400). This was the only risk variant with an allele fre-
quency > 5% in EA individuals in the NBS gene set. The
secondmost common pathogenic variant (allele frequency
~ 4.2%) in EA individuals was c.1330G>C (p.Asp444His)
(rs13078881) in BTD (MIM 609019), mutations in which188 The American Journal of Human Genetics 95, 183–193, August 7underlie biotinidase deficiency (MIM 253260). The most
common variant (allele frequency ¼ 4.0%) in AA individ-
uals was c.20T>A (p.Glu7Val) (rs334) in HBB (MIM
141900), mutations in which cause sickle cell anemia
(MIM 603903).
The mean number of risk alleles per individual in the
ARMD gene set was 3.16 (3.00 for EA individuals and
3.48 for AA individuals). Almost every individual (i.e.,
99.98%) carried at least one risk allele, and more than
half carried more than three risk alleles in the ARMD
gene set (Figure 3B). Four variants had allele frequencies
> 20% in EA individuals, and three variants in AA individ-
uals had allele frequencies> 20%. These four variants were
located in either C3 (MIM 120700) or CFH (MIM 134370)
(Table S8). The maximum number of ARMD risk alleles
per person was seven in both EA (n ¼ 2) and AA (n ¼ 1)
individuals.
The mean individual burden of known functional alleles
in the PGx gene set was 11.5 (11.1 for EA individuals and
12.3 for AA individuals; Figure 3C). Each individual carried
at least five known functional PGx alleles, and every AA in-
dividual carried at least six. The maximum number of
known functional alleles per individual in the PGx gene
set was 22 in EA individuals (n ¼ 1) and 20 in AA individ-
uals (n ¼ 4). The frequency spectrum of PGx risk variants
was fairly flat, suggesting that both rare and common var-
iants contributed to the overall burden of risk (Figure S3;
Table S8).
Across the NBS, ARMD, and PGx gene sets, the mean
burden of risk alleles per individual was 15.3 (14.7 for EA
individuals and 16.3 for AA individuals; Figure 3D). The
overall estimate of burden was largely unchanged with
the use of the more conservative NBS variant list (14.9:
14.3 in EA individuals and 16.0 in AA individuals). The
range of risk alleles per individual varied widely. The min-
imum was five for EA individuals (n ¼ 1) and seven for AA
individuals (n ¼ 1), and the maximum was 26 in both EA
(n ¼ 2) and AA (n ¼ 1) individuals. These estimates repre-
sent a ‘‘snapshot’’ of the total burden of risk alleles to be
found in any single individual but underscore the conten-
tion that every individual has alleles of potential clinical
utility.
Carrier Burden for Severe Recessive Disorders
of Childhood
Over the past several decades, attempts have been made to
estimate the burden of deleterious variants per individual
with the use of computational and/or population-genetic
approaches.20,21,43 More recently, next-generation
sequencing has enabled screening of relatively large
numbers of genes that underlie disease-related traits inhun-
dreds to thousands of individuals for estimating empirical
burden.19 One estimate that has been widely cited is that
by Bell et al.,19 who reported that individuals carry, on
average, 2.8 alleles for severe (i.e., causing substantial
morbidity or reduced lifespan) autosomal-recessive pediat-
ric disorders on the basis of a sampling of 437 genes in, 2014
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Figure 3. Plots of the Number of Pathogenic or Risk Variants per Individual
AA individuals are in blue, and EA individuals are in red. Plots are shown for NBS (A), ARMD (B), and PGx (C) gene sets and a combi-
nation across gene sets (D).104 individuals. Their criteria for assessing whether a
variant conferred risk of disease were conservative in that
they excluded HGMD variants not listed as ‘‘DM,’’ variants
withMAFR 5%, and variants observed to be homozygous.
Yet, 76 of the individuals sampled by Bell et al. were either
known to be carriers or affected by a severe childhood reces-
sive disorder, and the authors didnot adequately control for
the excess of pathogenic alleles in those individuals.
Using the same approach as Bell et al.19 but limiting the
individuals assessed to the 26 ‘‘controls’’ in their sample
and the 35 genes with ‘‘severe pediatric recessive muta-
tions,’’ we found that the burden of risk alleles, excluding
indels, was 1.73 instead of 2.8. This result suggests that
their original calculation was biased upward in part by
their inclusion of known affected and carrier individuals.
Moreover, a sample size of 26 individuals is very small
and prone to sampling bias. We therefore repeated the
analysis for 10,000 subsamples of 26 ESP6500 individuals,
excluding CF individuals from the calculations involvingThe AmerCFTR, to generate a distribution of 10,000 estimates of
the carrier burden of severe pediatric recessive mutations.
None of the average carrier burdens were close to the
1.73 we obtained by using their controls. Specifically, the
average number of risk alleles per individual was 0.68
(SD ¼ 0.17), and the maximum was 1.5. Results from our
curation strategy on the same 35 genes were similar. The
average carrier burden was 0.69 (SD ¼ 0.16), and the
maximum was 1.5. Accordingly, we think that ~0.7 is
most likely a more reliable estimate of the burden of risk al-
leles for severe childhood recessive disorders.Discussion
Each of the 70 genes that we assessed contained known
pathogenic variants, and every individual had several al-
leles (with potential clinical utility) that could be offered
for return. This is an often-stated result with little, if any,ican Journal of Human Genetics 95, 183–193, August 7, 2014 189
empirical support. Moreover, our results most likely under-
estimate the number of risk alleles in each of the three gene
sets (NBS, ARMD, PGx), much less each individual, because
we did not have the opportunity to include pathogenic in-
dels (e.g., DF508-CFTR) in our analysis, and accurate cura-
tion was limited by the quality and incompleteness of ex-
isting risk-variant databases, specifically HGMD, OMIM,
and LSDBs. These databases are imperfect because esti-
mates of allele frequencies in populations of non-European
ancestry are often incomplete, and it is challenging to
populate databases efficiently with up-to-date curated
variant information. Indeed, the development of accurate
and accessible variant databases will be critical to efforts to
report both primary and incidental results from ES/WGS.
Our estimate of the carrier burden for severe recessive
childhood disorders was 0.57, significantly less than the es-
timate of 2.8 variants per person for severe autosomal-
recessive disorders reported by Bell et al.19 Although the
genes we analyzed were not identical, we demonstrated
that their estimate was biased upward because of their
small sample size and by the inclusion of individuals
who were ascertained because they were affected by aMen-
delian disorder. The relatively large size of the ESP6500
data set enabled more accurate estimates of variant fre-
quencies and improved detection of rare variants, at least
in populations of European and African ancestry.
Our findings challenge the assumption that actionable
incidental results, much less incidental results of potential
clinical utility, in ES/WGS are rare. Indeed, they are rare
only to the extent that the search is limited to those
most likely affected by highly penetrant phenotypes.
Empirical confirmation that incidental results of potential
clinical utility are common in ES/WGS data is important
because ES/WGS are being used in a variety of healthcare
settings, including the evaluation of children with birth
defects, developmental delay, or autism; the assessment
of family risk of cancer and cancer profiling for personal-
izing therapeutics and delivering precision medicine; and
the evaluation of adult-onset conditions, such as cardio-
myopathy. Our results bring into better focus both the
potential benefit of offering incidental results from ES/
WGS to study participants, individuals, and families un-
dergoing clinical care and the potential reporting burden
that could be borne by clinicians. These findings, coupled
with professional attitudes and concerns about the return
of results,16 highlight the potential need for future recom-
mendations and guidelines for considering the return of
results to broader groups of individuals, including
‘‘healthy’’ individuals.
Our findings also undermine the notion that curating
and/or reporting known risk alleles is an added burden to
a service lab beyond what is required to answer a clinical
question. Manual curation of the variants in ESP6500
was, of course, labor intensive, but annotating ES/WGS
data for the 399 validated risk variants was computation-
ally trivial. Development of comprehensive databases of
validated risk variants is a major goal of multiple national190 The American Journal of Human Genetics 95, 183–193, August 7and international efforts, and using such databases to
annotate ES/WGS data in order to identify a primary result
is standard practice in exome service laboratories.
Existing approaches to returning genetic results are not
optimal for the return of large numbers of results with
the breadth and scope (i.e., that influence a wide spectrum
of phenotypes across the life of an individual) that we have
demonstrated could be offered for return. Whether to re-
turn all or some incidental results and, if only some, which
results to return, how to most effectively return them, and
how best to use them to benefit health are unknown. The
lack of such information is a major gap in knowledge in
empowering individuals and families to translate genomic
information into improved lifestyles, medical care, and ul-
timately long-term health. This problem is compounded
further by challenges to the traditional process of commu-
nicating and disseminating genetic results.
Traditionally, genetic and genomic test results are usually
communicated from provider to individual or family via
mail, phone, or face-to-face contact. However, the volume
of results and information is typically far in excess of staff-
ing allocations at many institutions, resulting in long de-
lays for the return of result information (National Society
of Genetic Counselors 2014 Professional Status Survey Ex-
ecutive Summary).44,45 This delay and the resultant
inability to act on the information can compromise patient
safety, increase the risk of a poor clinical outcome, and
disenfranchise families. Furthermore, with existing ap-
proaches to returning results, there are often few, if any,
convenient and inexpensive ways for a provider to ensure
that an individual and/or family has received and under-
stood a result. This situation will continue to worsen,
perhaps exponentially, as the use of ES/WGS in both
research and clinical settings continues to expand. The
countervailing concern is that the return of such incidental
results might increase unnecessary follow-up costs.46
Although this would certainly be a concern in the context
of a policy mandating the return of results, this empirical
question remains open in the context of offering secondary
results that hold a range of clinical and personal utility.
A number of alternative strategies for the return of results
from ES/WGS are under development and/or being tested
empirically.47,48 These strategies mustmeet the needs of in-
dividuals and families undergoing genetic testing and pro-
viders and institutions returning the genetic results. We
haveadvocated for theuseof individual- and family-focused
web-based tools for self-guidedmanagement of genetic and
genomic results such thatES/WGS results are framedas a dy-
namic resource of information that is managed by individ-
uals in partnership with their healthcare providers.47 These
approaches present ES/WGS results as a resource rather than
a test, recognize that the utility of results will vary over time
atdifferent stagesof life, anddescribe results in suchawayas
to make them more accessible and informative without
excessively reducing their medical impact.
We were able to overcome several limitations of
previous studies: (1) small sample sizes, ranging from 30, 2014
to 1,000 individuals;17,19,21,43 (2) analysis of primarily
affected individuals;19 (3) analysis of lower-coverage
exomes;21,43 (4) analysis of only known genotypes20 or
targeted sequencing;19 and (5) analysis of only genes asso-
ciated with autosomal-recessive conditions.19,20 Neverthe-
less, there are several important limitations to this work.
First, the ESP6500 data set is derived from exomes of indi-
viduals with heart, lung, and blood phenotypes. Therefore,
our resultsmight not be fully generalizable to other popula-
tions. In particular, the variants identified, allele fre-
quencies, andburden calculationsmight be underestimates
for younger, specifically newborn, populations, given that
most early-onset disorders and conditions that cause early
death (e.g., <18 years of age) were not included in the co-
horts sequenced by the ESP. Second, because the ESP
sampled mainly individuals who self-identified as EA or
AA, burden estimates of variants of utility in other popula-
tions (e.g., Asian Americans, Hispanic Latinos, Ashkenazi
Jews, etc.) most likely differ. Third, wewere unable to assess
CNVs and indels in the ESP6500 cohort. For this reason, our
burden calculations are probably underestimates and are
unlikely to fully capture the potential burden of pathogenic
variants for these three gene categories.
In summary, we have demonstrated that every exome
can be expected to contain variants of potential clinical
utility. Considering only those affected by highly pene-
trant actionable disorders, as suggested by the ACMG,
would result in the return of incidental results from
ES/WGS to only 1%–3% of the population. Expanding
the return to include conditions such as those studied
here has the potential to increase the value of ES/WGS
because of its possible large-scale consequences on the
effective practice of medicine. To this end, we think that
efforts should focus on providing individuals with the op-
portunity to make educated choices about whether they
would like to receive incidental results from ES/WGS
and, if so, what kinds. In turn, this will require the develop-
ment and testing of tools for effectively exercising this au-
tonomy, allowing individuals in partnership with their
healthcare providers to utilize genomic information as a
resource over their lifespans for disease prevention, treat-
ment, reproductive planning, and other psychosocial ben-
efits. Finally, a more inclusive focus on curating risk
variants in populations other than EA individuals is imper-
ative for providing these potential benefits to all popula-
tions, especially underserved minorities.Supplemental Data
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